Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Masamitsu, Nakao"'
Autor:
Yoshihito Uchida, Masamitsu Nakao, Shunsuke Yamada, Shohei Tsuji, Hayato Uemura, Jun-ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida
Publikováno v:
PLoS ONE, Vol 17, Iss 2 (2022)
Background To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. Methods A total of 103 patients with serum
Externí odkaz:
https://doaj.org/article/6a3a4833242d41afb6d9d5ac9d3e3864
Autor:
Yoshihito Uchida, Yukinori Imai, Shohei Tsuji, Hayato Uemura, Jun‐ichi Kouyama, Kayoko Naiki, Satsuki Ando, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Suguru Mizuno, Tomoaki Tomiya, Satoshi Mochida
Publikováno v:
Hepatology Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::171f552a249b661859996a9d0c6508c0
https://doi.org/10.1111/hepr.13926
https://doi.org/10.1111/hepr.13926
Autor:
Yoshihito Uchida, Yukinori Imai, Shohei Tsuji, Hayato Uemura, Jun-ichi Kouyama, Kayoko Naiki, Satsuki Ando, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Suguru Mizuno, Tomoaki Tomiya, Satoshi Mochida
Aim: To determine the significance of the portal venous blood flow and portosystemic shunts in patients with decompensated cirrhosis due to HCV infection following SVR achievement. Methods: Portal hypertension-related events and liver function were e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d07940e18c9f80a1d0a571ee8b3d877
https://doi.org/10.21203/rs.3.rs-2423520/v1
https://doi.org/10.21203/rs.3.rs-2423520/v1
Autor:
Yoshihito Uchida, Kayoko Naiki, Jun-Ichi Kouyama, Kayoko Sugawara, Masamitsu Nakao, Daisuke Motoya, Mie Inao, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205600 (2018)
AIMS:Liver injury can occur during antiviral therapies with direct-acting antivirals (DAAs), potentially necessitating discontinuation of the therapies, with consequent worsening of the sustained viral response (SVR) rates, in patients with hepatitis
Externí odkaz:
https://doaj.org/article/67a6ad365b4a41b4906a1879175a2116
Autor:
Yoshihito Uchida, Hayato Uemura, Shohei Tsuji, Shunsuke Yamada, Jun‐ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 52(5)
The Japanese guidelines for the treatment of cirrhosis suggest zinc supplementation to prevent hepatic encephalopathy in patients with cirrhosis and zinc deficiency, although the factors that are associated with therapeutic efficacy remain unknown.A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb767468caa2135a1803f549f9c4db23
https://pubmed.ncbi.nlm.nih.gov/35113468
https://pubmed.ncbi.nlm.nih.gov/35113468
Autor:
Yoshihito Uchida, Masamitsu Nakao, Shunsuke Yamada, Shohei Tsuji, Hayato Uemura, Jun-ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida
Publikováno v:
PloS one. 17(2)
Background To evaluate the long-term efficacy of switching of the nucleos(t)ide analog used for treatment from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in patients with chronic HBV infection. Methods A total of 103 patients with serum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2292cc2f623e4ff17d2bde2c5f2395fe
https://pubmed.ncbi.nlm.nih.gov/35180213
https://pubmed.ncbi.nlm.nih.gov/35180213
Autor:
Hayato Uemura, Yukinori Imai, Tomoaki Tomiya, Kayoko Naiki, Shohei Tsuji, Masamitsu Nakao, Nobuaki Nakayama, Jun-ichi Kouyama, Daisuke Motoya, Kayoko Sugawara, Satoshi Mochida, Yoshihito Uchida
Publikováno v:
Hepatology Research. 49:1083-1087
A 42-year-old Chinese man with chronic hepatitis C virus (HCV) infection visited our hospital for antiviral therapy. The subgenotype could not be determined using the HCV GENOTYPE Primer Kit (Institute of Immunology, Tokyo, Japan), which can identify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0453bf448e8c507305324059b0b44085
https://doi.org/10.1111/hepr.13339
https://doi.org/10.1111/hepr.13339
Autor:
Yoshihito Uchida, Mie Inao, Shohei Tsuji, Hayato Uemura, Jun‐ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 50(12)
To optimize the therapeutic strategy for patients with decompensated cirrhosis manifesting hepatic ascites and/or edema, factors affecting the outcome of patients receiving tolvaptan were evaluated.The subjects were 165 patients receiving tolvaptan i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19560d9f0d237a972bf21952b6ded5d7
https://pubmed.ncbi.nlm.nih.gov/32886950
https://pubmed.ncbi.nlm.nih.gov/32886950
Autor:
Jun-ichi Kouyama, Hayato Uemura, Nobuaki Nakayama, Kayoko Naiki, Yoshihito Uchida, Shohei Tsuji, Yukinori Imai, Satoshi Mochida, Masamitsu Nakao, Tomoaki Tomiya, Mie Inao, Kayoko Sugawara
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 50(11)
AIM To optimize the therapeutic strategy for patients with decompensated cirrhosis manifesting hepatic ascites and/or edema, factors affecting the outcome of patients receiving tolvaptan were evaluated. METHODS The subjects were 165 patients receivin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3cb59a61f99e51da0100e7356e7d3d5
https://pubmed.ncbi.nlm.nih.gov/32833292
https://pubmed.ncbi.nlm.nih.gov/32833292
Autor:
Manabu Nakazawa, Yukinori Imai, Yoichi Saito, Masamitsu Nakao, Yohei Fujii, Hayato Uemura, Satoshi Mochida, Yoshihito Uchida, Mie Inao, Tomoaki Tomiya, Kayoko Sugawara, Keisuke Shiokawa, Kayoko Naiki, Daisuke Motoya, Shinpei Yamaba, Nobuaki Nakayama, Satsuki Ando, Jun-ichi Kouyama, Hiroshi Uchiya, Akira Fuchigami
Publikováno v:
Hepatology Research. 48:233-243
Aim To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead-in interferon (IFN)-β injections was formulated according t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f814bced0f65a2b3e0b88c6a2c83afa
https://doi.org/10.1111/hepr.12980
https://doi.org/10.1111/hepr.12980